Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health, committed to innovating and delivering products and services to improve the health and wellness of both farm animals and pets. Established with nearly 70 years of heritage, Elanco operates in over 90 countries with a diverse portfolio of approximately 200 brands. Their core mission is encapsulated in their vision: 'Food and Companionship Enriching Life,' which they pursue through three primary avenues:
- Enhancing food security by improving the health and productivity of farm animals, thereby contributing to a safer, more affordable, and abundant food supply.
- Helping pets live longer, healthier lives through advanced veterinary products.
- Improving food safety standards globally.
Elanco’s dedication to animal health is reflected in their continuous innovation and quality systems, driven by a shared vision of enhancing life for animals and humans alike. This commitment is evident in their recent achievements and ongoing projects. For instance, Elanco's collaboration with Agtech company, Cattler, aims to provide data-driven solutions to cattle farmers, enhancing operational efficiency and productivity through services like Benchmark™ and Experior™.
Elanco's financial health is strong, with the company reporting consistent revenue growth and strategic investments aimed at future expansion. In their recent financial results, Elanco posted a 5% growth in the fourth quarter and strengthened their commercial infrastructure to support ongoing and future growth. They also announced the divestiture of their aqua business to streamline operations and focus on core areas, which is expected to reduce their debt leverage significantly by year-end.
Environmental sustainability is another critical focus for Elanco. Their recent partnership with Athian to create a livestock carbon insetting marketplace is a significant step towards reducing greenhouse gas emissions in the dairy and beef industries. Products like Bovaer®, which significantly reduce methane emissions from cattle, exemplify Elanco's commitment to sustainable farming practices.
Overall, Elanco continues to be at the forefront of animal health innovation, with substantial investments in R&D, strategic partnerships, and a clear commitment to sustainability and community health.
Elanco Animal Health (NYSE: ELAN) has announced its participation in three upcoming investor conferences in February and March 2025. Todd Young, executive vice president and CFO, will participate in fireside chats at the Bank of America Animal Health Summit on February 27 at 12:30 p.m. ET and the Barclays Global Healthcare Conference on March 11 at 9:00 a.m. ET.
Jeff Simmons, president and CEO, will join a fireside chat at the TD Cowen Annual Health Care Conference on March 3 at 3:10 p.m. ET. All sessions will be available via live audio webcasts in the 'Events and Presentations' section of Elanco's investor website, with replays available for a time after each event.
Elanco Animal Health (NYSE: ELAN) has launched Pet Protect, a new line of veterinarian-formulated supplements for dogs and cats. The launch comes as the U.S. pet supplement market reached $2.7 billion in 2023, growing at a CAGR of 20% over the past five years.
The Pet Protect line includes products for joint health, multivitamins, digestive function, calming, and skin health. Notable products include the Synovi G3 formula for joint health, DVM Daily Soft Chews for overall wellness, Lactoquil for digestive health, and a fast-acting Tranquilify™ blend for situational stress that works within 30 minutes.
The product line leverages the reputation of the Advantage brand, which has been a trusted leader in pet health for 25 years. Pet Protect is distinguished by being veterinarian-formulated, science-backed, and has earned the NASC® quality seal.
Elanco Animal Health has received a warning letter from the FDA regarding promotional materials for Zenrelia™, their prescription medication for dogs. The letter addresses statements in promotional materials for the drug, which is used to control itching and inflammation associated with skin allergies in dogs over 12 months old.
The company states they are working to review and update the promotional materials as requested, while emphasizing that the warning is not related to the product's actual performance in the market. Elanco maintains its financial outlook, expecting mid-single digit organic constant currency revenue growth in 2025, and does not anticipate material impact on Zenrelia revenue.
Important safety information for Zenrelia includes warnings about vaccine-induced disease risks and the need to discontinue use 28 days to 3 months prior to vaccination. The medication carries risks of infections and neoplastic conditions, with common side effects including vomiting, diarrhea, and tiredness.
Elanco Animal Health (NYSE: ELAN) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 25, 2025. The company will host a conference call at 8:00 a.m. eastern time to discuss the results with investors, media, and the general public.
A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the call concludes.
Elanco Animal Health (NYSE: ELAN) introduces Zenrelia™, an FDA-approved once-daily oral JAK inhibitor for controlling itching associated with allergic dermatitis in dogs aged 12+ months. The treatment, launched in September 2024, addresses a significant market with approximately 17 million U.S. dogs suffering from allergic skin diseases.
A newly published study in Veterinary Dermatology compared Zenrelia to Apoquel® in over 300 allergic dogs. The medication includes a boxed warning regarding concurrent vaccine administration. Real-world cases demonstrate successful treatment outcomes, with several dogs showing significant improvement in their conditions, including reduced itching and fur regrowth.
According to a survey, 82% of pet owners with itchy dogs dream of returning to normal life with their pets. The company has launched a dedicated platform, ZenreliaForVets.com, for U.S. veterinarians to learn more and place orders.
Elanco Animal Health (NYSE: ELAN) has launched Credelio Quattro, a new monthly chewable tablet for dogs that provides six-in-one parasite protection. The product is the first of its kind to protect against tapeworms, roundworms, hookworms, heartworms, ticks, and fleas in a single tablet.
The launch marks a significant milestone as it completes Elanco's portfolio of six potential blockbuster products in the U.S. market. According to company research, 94% of dog owners prioritize proactive treatment for intestinal worms. Studies show Credelio Quattro is 100% efficacious against tapeworms and kills ticks twice as fast as competing products.
The product addresses a significant market gap, as only one-third of pet owners believe fleas and ticks are a year-round risk, and only half provide year-round heartworm protection.
Elanco Animal Health (NYSE: ELAN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Tuesday, January 14, 2025. Jeff Simmons, president and CEO, will represent the company and engage with analysts during a Q&A session at 3:00 p.m. PST (6:00 PM EST).
The event will be accessible through a live audio webcast on the 'Events and Presentations' section of Elanco's investor website, with a replay available for approximately 30 days following the presentation.
Elanco celebrates its annual Global Day of Purpose (GDOP) with over 150 volunteer events worldwide. During October's Global Month of Purpose, employees contributed more than 11,000 volunteer hours through various initiatives. Notable activities include: The Warsaw team building animal enrichment items for the local zoo; 500 employees at Indianapolis HQ packing 100,000 meals for Rise Against Hunger; Taiwan team removing invasive plants; Japan conducting local cleanups; and Italy supporting charities and animal shelters.
The initiative has evolved from a single day to become a year-round program, with employees participating in activities ranging from river and park cleanups to animal shelter support and environmental conservation efforts, demonstrating Elanco's commitment to improving the lives of animals, people, and the environment.
Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. Todd Young, executive vice president and CFO, will participate in:
- A fireside chat at the Evercore ISI 7th Annual HealthCONx on Tuesday, December 3, at 11:15 a.m. ET
- The Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, at 1:30 p.m. ET
Live audio webcasts will be accessible through Elanco's investor website under 'Events and Presentations,' with replays available for approximately 30 days.
Dr. Elise Kelly, a veterinarian at Elanco Animal Health, discovered the presence of potentially deadly Echinococcus tapeworms in wild animal feces in her Missouri backyard. This finding highlights a significant but often overlooked threat to both pets and humans. According to an Elanco survey, nearly half of dog owners are unaware that their pets face year-round intestinal worm risks, while 73% prefer preventive protection over reactive treatment. The company promotes Interceptor Plus, a monthly chew that protects dogs against five common types of worms, including heartworm disease, hookworm, roundworm, tapeworm, and whipworm infections.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
What is Elanco Animal Health's core mission?
In how many countries does Elanco operate?
What recent collaborations has Elanco engaged in?
What is the significance of Elanco's partnership with Athian?
What are some of Elanco's notable products?
How is Elanco addressing sustainability in animal farming?
What financial goals has Elanco set for 2024?
How does Elanco contribute to food safety?
What is Elanco's approach to innovation?
How does Elanco support the health and wellness of pets?
